Merz Aesthetics has announced the commercial launch of Radiesse (+) Lidocaine, an injectable implant for deep injection for soft tissue augmentation to improve moderate to severe loss of jawline contour in adults over the age of 21.The injectable treatment is FDA-approved and is the first-and-only FDA-approved injectable treatment for jawline contour improvement. Radiesse and Radiesse (+), are aesthetic calcium hydroxylapatite (CaHA) products that have shown improvements in lower face wrinkles and folds along with long-term results due to stimulation of collagen and elastin production. CaHA has properties shown to provide immediate improvement as well as long-term results due to stimulation of collagen and elastin production in lower face wrinkles and folds. Radiesse, is an injectable biostimulator for correction of moderate to severe lower face wrinkles and folds and for improvement of volume loss in the dorsum of the hands. Radiesse (+) is also approved for moderate to severe lower face wrinkles and folds. The new jawline contour indication for Radiesse (+) is based on a Phase 3 study evaluating safety and effectiveness, with 75.6 percent of trial subjects achieving improvement on the Merz Jawline Assessment Scale (MJAS) on both jawlines compared to baseline as assessed by blinded evaluators.
Related Articles
Merz Aesthetics Launches Confidence Initiative
Merz Aesthetics Launches New Belotero Balance (+) With Lidocaine
Merz Aesthetics And Candela Corporation Announce Commercial Collaboration